Another one bites the dust: Novartis, Molecular Partners and their antiviral get the boot from NIH Covid study
Molecular Partners CEO Patrick Amstutz knew going into the NIH’s ACTIV-3 study that the bar for ensovibep was “very high.” A slew of Covid-19 antibodies had already flunked out of the trial — and though their Novartis-backed antibody alternative was different, he expressed cautious hope.
On Tuesday, however, he revealed that ensovibep didn’t clear that bar.
Ensovibep’s ACTIV-3 days are over after failing a futility analysis in hospitalized Covid-19 patients, the company announced. The molecule comes from a class of drugs developed by Molecular Partners that aims to perform the same functions as antibodies with far more target specificity and antiviral protection.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.